Department of Rheumatology, University Hospital Basel, Basel, Switzerland.
Department of Medicine, University of California.
Rheumatology (Oxford). 2017 Sep 1;56(9):1484-1491. doi: 10.1093/rheumatology/kex185.
Pneumococcal, tetanus and influenza vaccinations are recommended for patients with cryopyrin-associated periodic syndromes (CAPS) when treated with immunosuppressive medication. The aim of this publication is to report the safety of pneumococcal and other vaccinations in CAPS patients.
All CAPS patients followed in the β-CONFIDENT (Clinical Outcomes and Safety Registry study of Ilaris patients) registry were analysed if they had received a vaccination. The β-CONFIDENT registry is a global, long-term, prospective, observational registry, capturing and monitoring patients treated with canakinumab.
Sixty-eight CAPS patients had received a total of 159 vaccine injections, 107 injections against influenza, 19 pneumococcal vaccinations, 12 against tetanus/diphtheria antigens and 21 other vaccinations. Fourteen per cent of injections had elicited at least one vaccine reaction. All five vaccine-related serious adverse events were associated with pneumococcal vaccination. Vaccine reactions were observed in 70% of pneumococcal vaccinations, compared with 7% in influenza and 17% in tetanus/diphtheria vaccinations. The odds ratios to react to the pneumococcal vaccines compared with influenza and tetanus/diphtheria vaccines were 31.0 (95% CI: 8, 119) and 10.8 (95% CI: 2, 74). Vaccine reactions after pneumococcal vaccinations were more severe and lasted significantly longer (up to 3 weeks) compared with other vaccinations. In two patients, pneumococcal vaccination also elicited symptoms consistent with systemic inflammation due to CAPS reactivation.
Pneumococcal vaccines, unlike other vaccines, frequently trigger severe local and systemic inflammation in CAPS patients. Clinicians must balance potential benefits of pneumococcal immunization against safety concerns. The 13-valent pneumococcal conjugate vaccine might be favourable over the polysaccharide vaccine in CAPS patients.
当使用免疫抑制药物治疗时,建议对患有 Cryopyrin 相关周期性综合征(CAPS)的患者进行肺炎球菌、破伤风和流感疫苗接种。本出版物的目的是报告 CAPS 患者接种肺炎球菌疫苗和其他疫苗的安全性。
如果接受过疫苗接种,对在 β-CONFIDENT(依那西普患者的临床结果和安全性注册研究)注册中心接受治疗的所有 CAPS 患者进行分析。β-CONFIDENT 注册中心是一个全球性的、长期的、前瞻性的、观察性的注册中心,用于采集和监测接受卡那单抗治疗的患者。
68 名 CAPS 患者共接种了 159 剂疫苗,其中 107 剂流感疫苗、19 剂肺炎球菌疫苗、12 剂破伤风/白喉抗原疫苗和 21 剂其他疫苗。有 14%的注射至少引起了一次疫苗反应。所有 5 例与疫苗相关的严重不良事件均与肺炎球菌疫苗接种有关。肺炎球菌疫苗接种后观察到疫苗反应发生率为 70%,流感疫苗为 7%,破伤风/白喉疫苗为 17%。与流感和破伤风/白喉疫苗相比,肺炎球菌疫苗的反应发生率分别为 31.0(95%CI:8,119)和 10.8(95%CI:2,74)。与其他疫苗相比,肺炎球菌疫苗接种后的疫苗反应更严重,持续时间明显更长(最长达 3 周)。在 2 名患者中,肺炎球菌疫苗接种还引起了与 CAPS 再激活相关的全身性炎症的症状。
与其他疫苗不同,肺炎球菌疫苗在 CAPS 患者中经常引发严重的局部和全身炎症。临床医生必须权衡肺炎球菌免疫接种的潜在益处与安全性问题。在 CAPS 患者中,13 价肺炎球菌结合疫苗可能优于多糖疫苗。